Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Beam Therapeutics Inc. Director's Dealing 2021

Jul 9, 2021

31533_dirs_2021-07-08_4b9373f8-d4eb-4010-a7c7-e27d9faf5b21.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Beam Therapeutics Inc. (BEAM)
CIK: 0001745999
Period of Report: 2021-07-07

Reporting Person: Evans John M. (Director, CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-07-07 Common Stock M 25000 $1.03 Acquired 1046525 Direct
2021-07-07 Common Stock S 645 $100.69 Disposed 1045880 Direct
2021-07-07 Common Stock S 2300 $101.27 Disposed 1043580 Direct
2021-07-07 Common Stock S 100 $102.00 Disposed 1043480 Direct
2021-07-07 Common Stock S 2864 $103.52 Disposed 1040616 Direct
2021-07-07 Common Stock S 1336 $104.40 Disposed 1039280 Direct
2021-07-07 Common Stock S 1800 $105.44 Disposed 1037480 Direct
2021-07-07 Common Stock S 500 $106.48 Disposed 1036980 Direct
2021-07-07 Common Stock S 167 $107.31 Disposed 1036813 Direct
2021-07-07 Common Stock S 800 $108.65 Disposed 1036013 Direct
2021-07-07 Common Stock S 4800 $109.58 Disposed 1031213 Direct
2021-07-07 Common Stock S 3982 $110.54 Disposed 1027231 Direct
2021-07-07 Common Stock S 3456 $111.51 Disposed 1023775 Direct
2021-07-07 Common Stock S 2250 $112.62 Disposed 1021525 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-07-07 Stock Option (Right to Buy $1.03 M 25000 Disposed 2028-07-13 Common Stock (25000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 223000 Indirect

Footnotes

F1: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $100.25 to $100.99, inclusive.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $101.00 to $101.85, inclusive.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $103.21 to $103.96, inclusive.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $104.00 to $104.96, inclusive.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $105.02 to $105.98, inclusive.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $106.12 to $106.77, inclusive.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $107.29 to $107.33, inclusive.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $108.32 to $108.99, inclusive.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $109.01 to $109.98, inclusive.

F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $110.04 to $110.99, inclusive.

F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $111.04 to $111.99, inclusive.

F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $112.00 to $112.99, inclusive.

F15: The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested.